Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
Scott Dryden‐Peterson, Andy Kim, Arthur Y. Kim, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 77-84
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 9, pp. 790-798
Open Access | Times Cited: 302
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Zhujun Cao, Weiyi Gao, Hong Bao, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 5, pp. 406-417
Open Access | Times Cited: 187
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Jonathan J. Lau, Samuel M. S. Cheng, Kathy Leung, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 348-357
Open Access | Times Cited: 145
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Qian Zheng, Pengfei Ma, Mingwei Wang, et al.
Journal of Infection (2022) Vol. 86, Iss. 1, pp. 66-117
Open Access | Times Cited: 73
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 807-816
Open Access | Times Cited: 70
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45
SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1577-1585
Open Access | Times Cited: 44
Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
Matthew S. Durstenfeld, Michael J. Peluso, Feng Lin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Open Access | Times Cited: 27
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 46
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission
Liang En Wee, An Ting Tay, Calvin J. Chiew, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 10, pp. 1328-1333
Open Access | Times Cited: 26
Treatments for COVID-19
Hayden S. Andrews, Jonathan D. Herman, Rajesh T. Gandhi
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 145-157
Closed Access | Times Cited: 25
Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 11, pp. 1486-1497
Open Access | Times Cited: 23
Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infection
Min‐Hsiang Chuang, Jheng‐Yan Wu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 21
Treating Acute Covid-19 — Final Chapters Still Unwritten
Rajesh T. Gandhi, Martin Hirsch
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1234-1236
Open Access | Times Cited: 12
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID‐19 patients
Carlo Brogna, Luigi Montano, Maria Elisabetta Zanolin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Open Access | Times Cited: 9
Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population
Andrew D. Wilcock, Stephen M. Kissler, Ateev Mehrotra, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 1, pp. e235044-e235044
Open Access | Times Cited: 8
Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform
Bang Zheng, John Tazare, Linda Nab, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 19
Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19
Jheng‐Yan Wu, Mei‐Yuan Liu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Open Access | Times Cited: 17
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 17
Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series
Madison Breeden, Samuel L Aitken, Ji Hoon Baang, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 4
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top